{"id":788239,"date":"2023-10-04T19:01:49","date_gmt":"2023-10-04T23:01:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/"},"modified":"2023-10-04T19:01:49","modified_gmt":"2023-10-04T23:01:49","slug":"agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\u2019s healthcare company, today announced the granting of a previously disclosed inducement award to the Company\u2019s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company’s Compensation Committee and made as a material inducement to Mr. Coiante\u2019s entry into employment with the Company.<\/p>\n

In connection with the commencement of employment, Mr. Coiante received restricted stock units (\u201cRSUs\u201d) on October 4, 2023, to receive 20,000 shares of Agile Therapeutics, Inc. common stock.<\/p>\n

The RSUs have a 10-year term and a four-year vesting schedule and will vest in four equal installments over four years with the first installment vesting on the first anniversary of Mr. Coiante\u2019s start date and the RSUs being fully vested on the fourth anniversary of Mr. Coiante\u2019s start date, subject to Mr. Coiante\u2019s continued service with the Company on the applicable vesting date.<\/p>\n

\n About<\/strong>
\n Agile<\/strong>
\n Therapeutics,<\/strong>
\n Inc.<\/strong>
\n
Agile Therapeutics is a women’s healthcare company dedicated to fulfilling the unmet health needs of today\u2019s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla\u00ae<\/sup>, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion\u00ae<\/sup>, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com<\/a>. The Company may occasionally disseminate material, nonpublic information on the Company\u2019s website, Twitter account (@agilether<\/a>), and LinkedIn<\/a> account.<\/p>\n

\n Contact:<\/strong>
\n
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com<\/strong><\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\u2019s healthcare company, today announced the granting of a previously disclosed inducement award to the Company\u2019s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company’s Compensation Committee and made as a material inducement to Mr. Coiante\u2019s entry into employment with the Company. In connection with the commencement of employment, Mr. Coiante received restricted stock units (\u201cRSUs\u201d) on October 4, 2023, to receive 20,000 shares of Agile Therapeutics, Inc. common stock. The RSUs have a 10-year term and a four-year vesting schedule and will vest in four equal installments over four years with the first … <\/p>\n

Continue reading “Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-788239","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\u2019s healthcare company, today announced the granting of a previously disclosed inducement award to the Company\u2019s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company’s Compensation Committee and made as a material inducement to Mr. Coiante\u2019s entry into employment with the Company. In connection with the commencement of employment, Mr. Coiante received restricted stock units (\u201cRSUs\u201d) on October 4, 2023, to receive 20,000 shares of Agile Therapeutics, Inc. common stock. The RSUs have a 10-year term and a four-year vesting schedule and will vest in four equal installments over four years with the first … Continue reading "Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T23:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-10-04T23:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":307,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=\",\"datePublished\":\"2023-10-04T23:01:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\u2019s healthcare company, today announced the granting of a previously disclosed inducement award to the Company\u2019s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company’s Compensation Committee and made as a material inducement to Mr. Coiante\u2019s entry into employment with the Company. In connection with the commencement of employment, Mr. Coiante received restricted stock units (\u201cRSUs\u201d) on October 4, 2023, to receive 20,000 shares of Agile Therapeutics, Inc. common stock. The RSUs have a 10-year term and a four-year vesting schedule and will vest in four equal installments over four years with the first … Continue reading \"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-04T23:01:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-10-04T23:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/"},"wordCount":307,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/","name":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=","datePublished":"2023-10-04T23:01:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzkxMCM1ODU3OTA3IzIwMDc5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agile-therapeutics-reports-an-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=788239"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=788239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=788239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=788239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}